Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170685 | 0.85 | MRGPRX4 (0.49) | TPMTMRGPRX4GPR35ALOX15TSHR | |
| SCHEMBL2511327 | 0.85 | MRGPRX4 (0.45) | TPMTMRGPRX4GPR35ALOX15TSHR | |
| SCHEMBL5223887 | 0.84 | VNN1 (0.40) | TPMTHCAR1MRGPRX4GPR35VNN1 | |
| SCHEMBL16953692 | 0.82 | MAPT (0.45) | TPMTMRGPRX4GPR35TTRVNN1 | |
| SCHEMBL24156534 | 0.82 | PARP1 (0.46) | TPMTMRGPRX4GPR35VNN1TSHR | |
| SCHEMBL10412427 | 0.80 | TPMT (0.61) | TPMTHCAR1MRGPRX4GPR35HCAR2 | |
| SCHEMBL2071745 | 0.79 | GSK3B (0.40) | TPMTMRGPRX4GPR35VNN1TSHR | |
| SCHEMBL3488915 | 0.78 | ALDH1A1 (0.46) | MRGPRX4GPR35VNN1 | |
| SCHEMBL9821033 | 0.78 | GSK3B (0.39) | TPMTMRGPRX4GPR35VNN1TSHR | |
| SCHEMBL31207998 | 0.78 | ALDH1A1 (0.46) | MRGPRX4GPR35VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289685-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-09-15 | — | — | US | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2018066718-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | WO | disclosed |
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2535330-A2 | Iminopyridine derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-2222668-B1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2011-11-02 | — | — | EP | disclosed |
| CN-101945862-A | Tetrahydrocyclopenta [ b ] indol-3-yl carboxylic acid derivatives for the treatment of autoimmune and inflammatory disorders | ARENA PHARM INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| CN-1379775-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | TPMT 1471/4885HCAR1 65/4885MRGPRX4 297/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | TPMT 1471/4885HCAR1 65/4885MRGPRX4 297/4885 |
| US-20220289685-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | G6PD, DPYD, DHFR | TPMT 22/4885HCAR1 1326/4885MRGPRX4 1814/4885 |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | TPMT 814/4885HCAR1 26/4885MRGPRX4 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.